Glutamatergic gene variants impact the clinical profile of efficacy and side effects of haloperidol

Ina Giegling, Antonio Drago, Vita Dolžan, Blanka Kores Plesničar, Martin Schäfer, Annette M. Hartmann, Thomas Sander, Mohammad Reza Toliat, Hans Jürgen Möller, Hans H. Stassen, Dan Rujescu, Alessandro Serretti

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background The glutamatergic system may be relevant to the pathophysiology of psychosis and to the effects of antipsychotic treatments. Objectives We investigated a set of 62 SNPs located in genes coding for subunits of glutamatergic receptors (GAD1, GRIA1, GRIA3, GRIA4, GRID2, GRIK1, GRIK2, GRIK3, GRIK4, GRIN2B, GRM1 and GRM4), and the transporter of glycine (SLC6A5), as modulators of the effects of haloperidol. Methods and results We studied a sample of 101 acutely ill psychotic patients. We then validated our result in two independent samples from Slovenia (n = 71 and n = 118) of schizophrenic patients treated with antipsychotics. We both investigated the antipsychotic effect (Positive and Negative Syndrome Scale) and motor side effect (Extrapyramidal Symptom Rating Scale) at baseline and days 3, 7, 14, 21 and 28. SLC6A5 variant (rs2298826) was found to be associated with a rapid rise of motor side effects at the beginning of the treatment (repeated measures of analysis of variance, P = 0.0002), followed by a subsequent adaptation, probably dependent on haloperidol doses down titration. A specific effect was noted for dyskinetic symptoms. Haplotype analysis strengthened the relevance of SLC6A5: the C-A-C haplotype (rs1443548, rs883377, rs1945771) was found to be associated with higher Extrapyramidal symptom rating scale scores (overall P = 0.01, haplotype P = 0.000001). We successfully replicated this finding in the two independent samples from Slovenia. Conclusion This result further stresses the relevance of the glutamatergic system in modulating the effects of haloperidol treatment, especially with regards to motor side effects. Pharmacogenetics and Genomics 21:206-216.

Original languageEnglish
Pages (from-to)206-216
Number of pages11
JournalPharmacogenetics and Genomics
Volume21
Issue number4
DOIs
Publication statusPublished - Apr 2011

Fingerprint

Haloperidol
Haplotypes
Antipsychotic Agents
Slovenia
Glycine Plasma Membrane Transport Proteins
Genes
Pharmacogenetics
Genomics
Psychotic Disorders
Single Nucleotide Polymorphism
Analysis of Variance
Therapeutics

Keywords

  • Antipsychotic
  • Gene
  • Glutamatergic
  • Pharmacogenetics
  • Schizophrenia

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Genetics(clinical)

Cite this

Giegling, I., Drago, A., Dolžan, V., Plesničar, B. K., Schäfer, M., Hartmann, A. M., ... Serretti, A. (2011). Glutamatergic gene variants impact the clinical profile of efficacy and side effects of haloperidol. Pharmacogenetics and Genomics, 21(4), 206-216. https://doi.org/10.1097/FPC.0b013e32833efb18

Glutamatergic gene variants impact the clinical profile of efficacy and side effects of haloperidol. / Giegling, Ina; Drago, Antonio; Dolžan, Vita; Plesničar, Blanka Kores; Schäfer, Martin; Hartmann, Annette M.; Sander, Thomas; Toliat, Mohammad Reza; Möller, Hans Jürgen; Stassen, Hans H.; Rujescu, Dan; Serretti, Alessandro.

In: Pharmacogenetics and Genomics, Vol. 21, No. 4, 04.2011, p. 206-216.

Research output: Contribution to journalArticle

Giegling, I, Drago, A, Dolžan, V, Plesničar, BK, Schäfer, M, Hartmann, AM, Sander, T, Toliat, MR, Möller, HJ, Stassen, HH, Rujescu, D & Serretti, A 2011, 'Glutamatergic gene variants impact the clinical profile of efficacy and side effects of haloperidol', Pharmacogenetics and Genomics, vol. 21, no. 4, pp. 206-216. https://doi.org/10.1097/FPC.0b013e32833efb18
Giegling, Ina ; Drago, Antonio ; Dolžan, Vita ; Plesničar, Blanka Kores ; Schäfer, Martin ; Hartmann, Annette M. ; Sander, Thomas ; Toliat, Mohammad Reza ; Möller, Hans Jürgen ; Stassen, Hans H. ; Rujescu, Dan ; Serretti, Alessandro. / Glutamatergic gene variants impact the clinical profile of efficacy and side effects of haloperidol. In: Pharmacogenetics and Genomics. 2011 ; Vol. 21, No. 4. pp. 206-216.
@article{299d3104b5724f198f109d8dd0a5c2b1,
title = "Glutamatergic gene variants impact the clinical profile of efficacy and side effects of haloperidol",
abstract = "Background The glutamatergic system may be relevant to the pathophysiology of psychosis and to the effects of antipsychotic treatments. Objectives We investigated a set of 62 SNPs located in genes coding for subunits of glutamatergic receptors (GAD1, GRIA1, GRIA3, GRIA4, GRID2, GRIK1, GRIK2, GRIK3, GRIK4, GRIN2B, GRM1 and GRM4), and the transporter of glycine (SLC6A5), as modulators of the effects of haloperidol. Methods and results We studied a sample of 101 acutely ill psychotic patients. We then validated our result in two independent samples from Slovenia (n = 71 and n = 118) of schizophrenic patients treated with antipsychotics. We both investigated the antipsychotic effect (Positive and Negative Syndrome Scale) and motor side effect (Extrapyramidal Symptom Rating Scale) at baseline and days 3, 7, 14, 21 and 28. SLC6A5 variant (rs2298826) was found to be associated with a rapid rise of motor side effects at the beginning of the treatment (repeated measures of analysis of variance, P = 0.0002), followed by a subsequent adaptation, probably dependent on haloperidol doses down titration. A specific effect was noted for dyskinetic symptoms. Haplotype analysis strengthened the relevance of SLC6A5: the C-A-C haplotype (rs1443548, rs883377, rs1945771) was found to be associated with higher Extrapyramidal symptom rating scale scores (overall P = 0.01, haplotype P = 0.000001). We successfully replicated this finding in the two independent samples from Slovenia. Conclusion This result further stresses the relevance of the glutamatergic system in modulating the effects of haloperidol treatment, especially with regards to motor side effects. Pharmacogenetics and Genomics 21:206-216.",
keywords = "Antipsychotic, Gene, Glutamatergic, Pharmacogenetics, Schizophrenia",
author = "Ina Giegling and Antonio Drago and Vita Dolžan and Plesničar, {Blanka Kores} and Martin Sch{\"a}fer and Hartmann, {Annette M.} and Thomas Sander and Toliat, {Mohammad Reza} and M{\"o}ller, {Hans J{\"u}rgen} and Stassen, {Hans H.} and Dan Rujescu and Alessandro Serretti",
year = "2011",
month = "4",
doi = "10.1097/FPC.0b013e32833efb18",
language = "English",
volume = "21",
pages = "206--216",
journal = "Pharmacogenetics and Genomics",
issn = "1744-6872",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Glutamatergic gene variants impact the clinical profile of efficacy and side effects of haloperidol

AU - Giegling, Ina

AU - Drago, Antonio

AU - Dolžan, Vita

AU - Plesničar, Blanka Kores

AU - Schäfer, Martin

AU - Hartmann, Annette M.

AU - Sander, Thomas

AU - Toliat, Mohammad Reza

AU - Möller, Hans Jürgen

AU - Stassen, Hans H.

AU - Rujescu, Dan

AU - Serretti, Alessandro

PY - 2011/4

Y1 - 2011/4

N2 - Background The glutamatergic system may be relevant to the pathophysiology of psychosis and to the effects of antipsychotic treatments. Objectives We investigated a set of 62 SNPs located in genes coding for subunits of glutamatergic receptors (GAD1, GRIA1, GRIA3, GRIA4, GRID2, GRIK1, GRIK2, GRIK3, GRIK4, GRIN2B, GRM1 and GRM4), and the transporter of glycine (SLC6A5), as modulators of the effects of haloperidol. Methods and results We studied a sample of 101 acutely ill psychotic patients. We then validated our result in two independent samples from Slovenia (n = 71 and n = 118) of schizophrenic patients treated with antipsychotics. We both investigated the antipsychotic effect (Positive and Negative Syndrome Scale) and motor side effect (Extrapyramidal Symptom Rating Scale) at baseline and days 3, 7, 14, 21 and 28. SLC6A5 variant (rs2298826) was found to be associated with a rapid rise of motor side effects at the beginning of the treatment (repeated measures of analysis of variance, P = 0.0002), followed by a subsequent adaptation, probably dependent on haloperidol doses down titration. A specific effect was noted for dyskinetic symptoms. Haplotype analysis strengthened the relevance of SLC6A5: the C-A-C haplotype (rs1443548, rs883377, rs1945771) was found to be associated with higher Extrapyramidal symptom rating scale scores (overall P = 0.01, haplotype P = 0.000001). We successfully replicated this finding in the two independent samples from Slovenia. Conclusion This result further stresses the relevance of the glutamatergic system in modulating the effects of haloperidol treatment, especially with regards to motor side effects. Pharmacogenetics and Genomics 21:206-216.

AB - Background The glutamatergic system may be relevant to the pathophysiology of psychosis and to the effects of antipsychotic treatments. Objectives We investigated a set of 62 SNPs located in genes coding for subunits of glutamatergic receptors (GAD1, GRIA1, GRIA3, GRIA4, GRID2, GRIK1, GRIK2, GRIK3, GRIK4, GRIN2B, GRM1 and GRM4), and the transporter of glycine (SLC6A5), as modulators of the effects of haloperidol. Methods and results We studied a sample of 101 acutely ill psychotic patients. We then validated our result in two independent samples from Slovenia (n = 71 and n = 118) of schizophrenic patients treated with antipsychotics. We both investigated the antipsychotic effect (Positive and Negative Syndrome Scale) and motor side effect (Extrapyramidal Symptom Rating Scale) at baseline and days 3, 7, 14, 21 and 28. SLC6A5 variant (rs2298826) was found to be associated with a rapid rise of motor side effects at the beginning of the treatment (repeated measures of analysis of variance, P = 0.0002), followed by a subsequent adaptation, probably dependent on haloperidol doses down titration. A specific effect was noted for dyskinetic symptoms. Haplotype analysis strengthened the relevance of SLC6A5: the C-A-C haplotype (rs1443548, rs883377, rs1945771) was found to be associated with higher Extrapyramidal symptom rating scale scores (overall P = 0.01, haplotype P = 0.000001). We successfully replicated this finding in the two independent samples from Slovenia. Conclusion This result further stresses the relevance of the glutamatergic system in modulating the effects of haloperidol treatment, especially with regards to motor side effects. Pharmacogenetics and Genomics 21:206-216.

KW - Antipsychotic

KW - Gene

KW - Glutamatergic

KW - Pharmacogenetics

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=79955483855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955483855&partnerID=8YFLogxK

U2 - 10.1097/FPC.0b013e32833efb18

DO - 10.1097/FPC.0b013e32833efb18

M3 - Article

C2 - 20859245

AN - SCOPUS:79955483855

VL - 21

SP - 206

EP - 216

JO - Pharmacogenetics and Genomics

JF - Pharmacogenetics and Genomics

SN - 1744-6872

IS - 4

ER -